Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00187083 · ClinicalTrials.gov registry record · Phase 3
A Study of Children With Refractory or Relapsed ALL
A Phase 3 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT00187083: Completed Phase 3 study, sponsored by St. Jude Children's Research Hospital.
NCT00187083 is a Phase 3 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 40 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00187083, a Phase 3 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
The main purpose of this study is to find out which form of asparaginase (the native E. coli/Erwinia) or PEG-asparaginase) is more effective during induction treatment for children with acute lymphoblastic leukemia that has come back after treatment (relapsed) or is resistant to treatment (refractory)
Interventions
- DRUG Topotecan, dexamethasone, vincristine
- DRUG E. coli Asparaginase, PEG-L-asparaginase
- DRUG erwinia asparaginase
- DRUG fludarabine, methotrexate, mercaptopurine
- DRUG idarubicin, etoposide, cytarbine, teniposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1997-02 |
| Est. Completion | 2003-12 |
| Phase | Phase 3 |
What the finished NCT00187083 record still lists
NCT00187083 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Topotecan, dexamethasone, vincristine is the first listed.
NCT00187083 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00187083 about?
NCT00187083 is a clinical study titled "A Study of Children With Refractory or Relapsed ALL". The main purpose of this study is to find out which form of asparaginase (the native E. coli/Erwinia) or PEG-asparaginase) is more effective during induction treatment for children with acute lymphoblastic leukemia that has come back after treatment (relapsed) or is resistant to treatment (refractor...
What is the current status of trial NCT00187083?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 1997-02. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00187083?
The interventions under investigation include: Topotecan, dexamethasone, vincristine (DRUG), E. coli Asparaginase, PEG-L-asparaginase (DRUG), erwinia asparaginase (DRUG), fludarabine, methotrexate, mercaptopurine (DRUG), idarubicin, etoposide, cytarbine, teniposide (DRUG).
Who is sponsoring clinical trial NCT00187083?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00187083's enrollment target sits among peer trials
40 1878th of 2000 higher than 103 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia